Abstract
The management of metastatic renal-cell carcinoma (mRCC) represents an important clinical challenge. Since being approved in the early 1990s, aspecific immunotherapy has been a mainstay of treatment for mRCC and the only therapy that has demonstrated long-term cures for mRCC. However, in recent times there have been landmark advances made in the field of specific immunotherapy for a number of malignancies, including kidney cancer. This review outlines the range of immunobased agents currently available for the treatment of mRCC.
Original language | English (US) |
---|---|
Pages (from-to) | 83-93 |
Number of pages | 11 |
Journal | ImmunoTargets and Therapy |
Volume | Volume 6 |
DOIs | |
State | Published - 2017 |
Keywords
- cryosurgery
- immunocheckpoints
- immunotherapy
- kidney neoplasm
- targeted therapy
- vaccines
PubMed: MeSH publication types
- Journal Article
- Review